[Management of intraoperative floppy iris syndrome].
OBJECTIVE
To evaluate the incidence of IFIS in male patients whith alfa 1-AB treatment for benign prostatic hyperplasia (BPH) who underwent cataract surgery and also the pre and intraoperatory management and IFIS profilaxy.


METHODS
Iasi "Sf Spiridon" Emergency Hospital and "Oftaprof" private practice


METHODS
Observational retrospective study that took place over a period of 2 years (july 2009-july 2011) and reviewed 2484 eyes that underwent cataract surgery. A number of 1199 eyes were from 1049 male patients.


RESULTS
Out of the 1049 male patients, 139 (13,25%) underwent treatment for BHP using the medication as follows: 119 used tamsulosin (85,6%); 18 used doxazosin, (12,94%); 2 used alfuzosin (1,43%). Out of the 139 men, 32 (23,02%) showed IFIS but only the ones treated with tamsulosin. After introducing a surgical protocol that comprised of the use of large amounts of vascoelastic material (Viscoat), intracamerular fenilefrin (Mezaton), the use of iris retractors and low faco parameters the incidence and severity of IFIS was significantly reduced.


CONCLUSIONS
Correct evauation before surgery is necessary in order to anticipate the condition as its frequency and severity can be reduced by a proactive behavior which demands experience and adequate endowment.
Clinica i Oftalmologie a Spitalului Clinic de Urgenţe "Sf. Spiridon" Iaşi UMF "GR. T. Popa" Iaşi.
D
D
Chiseliţă
Alina
A
Cantemir
Lucia
L
Epifanov
Alexandra
A
Huţuleac
Alexandra
A
Irod
D058646:Adrenergic alpha-1 Receptor Agonists / Q000008:administration & dosage*; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000368:Aged; D002387:Cataract Extraction; D002809:Chondroitin Sulfates / Q000008:administration & dosage; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D015994:Incidence; D056965:Injections, Intraocular; D007430:Intraoperative Care; D007499:Iris Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D010656:Phenylephrine / Q000008:administration & dosage*; D011300:Preoperative Care; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011680:Pupil / Q000187:drug effects; D012189:Retrospective Studies; D012383:Romania / Q000453:epidemiology; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D013577:Syndrome; D000077409:Tamsulosin; D016896:Treatment Outcome
D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D004338:Drug Combinations; D013449:Sulfonamides; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D010656:Phenylephrine; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates; D000077409:Tamsulosin